^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

LT-171-861

i
Other names: LT-171-861
Associations
Trials
Company:
China Pharmaceutical University
Drug class:
FLT3 inhibitor
Related drugs:
Associations
Trials
over3years
Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP Inhibitor in multiple myeloma. (PubMed, Biochem Pharmacol)
Moreover, Olaparib, a PARP inhibitor, could enhance the antitumor effect of LT-171-861 in suppressing tumor growth in MM xenografted nude mice. Taken together, our results demonstrated that LT-171-861 showed a promising therapeutic potential for MM and had an additional lethal effect with PARP inhibitors.
Journal • PARP Biomarker
|
EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
|
Lynparza (olaparib) • LT-171-861
almost4years
LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. (PubMed, Theranostics)
We also show the efficacy of LT‑171-861 in a subcutaneous implantation model and a bone marrow engrafted model in vivo, where administration of LT-171-861 led to almost complete tumor regression and increased survival. Overall, this study not only identifies LT-171-861 as a potent FLT3 inhibitor, but also provides a rationale for the upcoming clinical trial of LT-171-861 in patients with AML and FLT3-ITD mutations.
Preclinical • Journal
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation • FLT3 mutation • FLT3 D835Y • FLT3 F691L • FLT3 D835 • FLT3 Y842C • FLT3 N676D
|
LT-171-861